❮ REPROCELL Corporate News

Corporate News

Author: Jean-Philippe Richard PhD, Stem Cell Director, REPROCELL USA

REPROCELL Announces the Commercial Launch of its StemEdit Hypoimmune hiPSC Lines Generated with Advanced Gene Editing Innovations

07 November 2025

REPROCELL announces the launch of new hypoimmune hiPSC lines using advanced gene-editing technologies, enhancing precision and efficiency in regenerative medicine and research applications.

1

Stem cell and drug discovery scientists around the world use our services and products in their preclinical and clinical research.

About REPROCELL

Corporate news by tag

  1. 3D Cell Culture
  2. Clinical Capabilities
  3. Drug Discovery
  4. Genomic Services
  5. GMP
  6. Human Tissue Samples
  7. Human Tissue Testing
  8. Life Sciences
  9. Master Cell Banks
  10. Pharmacology-AI
  11. Precision Medicine
  12. Product Catalog
  13. Regenerative Medicine
  14. Stem Cells
  15. Volunteer Registry

 Corporate news archive